AgingResearch.NewsJoin free

SRK-439

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab
  • Animals1

Outcomes

2

Grip strength

upin mice1

1 study

  1. SRK-439 improves grip strength in mice (+2.3% from baseline, p<0.01).

    “SRK-439-treated animals had improved grip strength from baseline by 2.3% (p<0.01).”

    Animals21 days

    The Anti-myostatin Antibody SRK-439 Improves Grip Strength during GLP-1RA Treatment in a Mouse Model of Obesity

    ADA Scientific Sessions 2025 abstract13 Jun 2025

Lean mass

upin mice1

1 study

  1. SRK-439 increases lean mass in mice.

    “SRK-439 increased lean mass and individual muscle weights, regardless of sema administration.”

    Animalsfive weeks

    The Anti-myostatin Antibody SRK-439 Improves Grip Strength during GLP-1RA Treatment in a Mouse Model of Obesity

    ADA Scientific Sessions 2025 abstract13 Jun 2025

Latest

Related